Literature DB >> 27186514

Cons: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with inoperable large volume stage III non-small cell lung cancer.

George Rodrigues1.   

Abstract

Entities:  

Year:  2016        PMID： 27186514      PMCID： PMC4858578          DOI： 10.21037/tlcr.2016.04.03

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  16 in total

1.  Are the results of RTOG 0617 mysterious?

Authors:  James D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-01       Impact factor: 7.038

Review 2.  Management of unresected stage III non-small cell lung cancer: a systematic review.

Authors:  Gordon Okawara; Jean A Mackay; William K Evans; Yee C Ung
Journal:  J Thorac Oncol       Date:  2006-05       Impact factor: 15.609

3.  Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.

Authors:  W Sause; P Kolesar; I V Taylor S; D Johnson; R Livingston; R Komaki; B Emami; W Curran; R Byhardt; A R Dar; A Turrisi
Journal:  Chest       Date:  2000-02       Impact factor: 9.410

4.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.

Authors:  K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

5.  Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.

Authors:  Walter J Curran; Rebecca Paulus; Corey J Langer; Ritsuko Komaki; Jin S Lee; Stephen Hauser; Benjamin Movsas; Todd Wasserman; Seth A Rosenthal; Elizabeth Gore; Mitchell Machtay; William Sause; James D Cox
Journal:  J Natl Cancer Inst       Date:  2011-09-08       Impact factor: 13.506

Review 6.  The evolving locally-advanced non-small cell lung cancer landscape: Building on past evidence and experience.

Authors:  Benoite Méry; Jean-Baptiste Guy; Aurélie Swalduz; Alexis Vallard; Cyril Guibert; Hweej Almokhles; Majed Ben Mrad; Romain Rivoirard; Alexander T Falk; Pierre Fournel; Nicolas Magné
Journal:  Crit Rev Oncol Hematol       Date:  2015-06-07       Impact factor: 6.312

7.  Definitive radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline.

Authors:  George Rodrigues; Hak Choy; Jeffrey Bradley; Kenneth E Rosenzweig; Jeffrey Bogart; Walter J Curran; Elizabeth Gore; Corey Langer; Alexander V Louie; Stephen Lutz; Mitchell Machtay; Varun Puri; Maria Werner-Wasik; Gregory M M Videtic
Journal:  Pract Radiat Oncol       Date:  2015 May-Jun

8.  Concurrent chemoradiotherapy for large-volume locally-advanced non-small cell lung cancer.

Authors:  Terry G Wiersma; Max Dahele; Wilko F A R Verbakel; Peter M van de Ven; Patricia F de Haan; Egbert F Smit; Ellen J F van Reij; Ben J Slotman; Suresh Senan
Journal:  Lung Cancer       Date:  2013-01-26       Impact factor: 5.705

9.  Non-small cell lung cancer in octogenarians: treatment practices and preferences.

Authors:  Geoffrey R Oxnard; Panos Fidias; Alona Muzikansky; Lecia V Sequist
Journal:  J Thorac Oncol       Date:  2007-11       Impact factor: 15.609

Review 10.  Preferences of lung cancer patients for treatment and decision-making: a systematic literature review.

Authors:  K Schmidt; K Damm; A Prenzler; H Golpon; T Welte
Journal:  Eur J Cancer Care (Engl)       Date:  2015-12-17       Impact factor: 2.520
View more
  1 in total

Review 1.  Proton therapy for non-small cell lung cancer: the road ahead.

Authors:  Eric D Brooks; Matthew S Ning; Vivek Verma; X Ronald Zhu; Joe Y Chang
Journal:  Transl Lung Cancer Res       Date:  2019-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.